Grant: Alliance Grants
Dalhousie University
$32,000.00
Exploiting Nickel Cross-coupling Catalysis for the Practical Synthesis and Functionalization of Pharmaceutically Relevant Organic Molecules
FY 2022-23
Summary
In the fast-paced drug discovery and development process, synthetic chemists require efficient methods of preparing complex organic molecules that contain carbon, hydrogen, and a diversity of 'heteroatoms' (e.g., nitrogen, oxygen, sulfur, fluorine and other elements) under mild, 'user-friendly' conditions. One method involves the use of metal catalysts that allow smaller portions of targeted organic molecules to be 'clipped together' in a process called cross-coupling, thus allowing for the assembly of potential active pharmaceutical ingredients (APIs) in a more streamlined and cost-effective manner. This collaborative research project will seek to exploit recent expertise in sustainable cross-coupling catalysis developed by the applicant's research group, in addressing specific unmet synthetic chemistry challenges faced by the industrial partner (Paraza Pharma Inc., Montreal, QC) with regard to the targeted synthesis and/or modification of heteroatom-dense compounds within proprietary APIs. In particular, the industrial partner requires the development of methodologies that make use of cheap and abundant reaction partners (e.g., heteroaryl chlorides), as well as Earth abundant catalysts (rather than precious metal catalysts that are commonly employed). Once developed, these synthetic protocols can be exploited directly by scientists at Paraza Pharma Inc. in proprietary API synthesis and functionalization. Success in this project will greatly accelerate the industrial partner's drug development program, thereby leading to more rapid identification of novel therapies to the benefit of all Canadians.
Program
Alliance Grants
Recipient
Location
Nova Scotia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
561675-2021
Name nom
Stradiotto, Mark MJ
Department département
Chemistry
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2021
Award amount
32000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Installment
inst:2
Partie
1
Nb partie
2
Application title
Exploiting Nickel Cross-coupling Catalysis for the Practical Synthesis and Functionalization of Pharmaceutically Relevant Organic Molecules
Application summary
In the fast-paced drug discovery and development process, synthetic chemists require efficient methods of preparing complex organic molecules that contain carbon, hydrogen, and a diversity of 'heteroatoms' (e.g., nitrogen, oxygen, sulfur, fluorine and other elements) under mild, 'user-friendly' conditions. One method involves the use of metal catalysts that allow smaller portions of targeted organic molecules to be 'clipped together' in a process called cross-coupling, thus allowing for the assembly of potential active pharmaceutical ingredients (APIs) in a more streamlined and cost-effective manner. This collaborative research project will seek to exploit recent expertise in sustainable cross-coupling catalysis developed by the applicant's research group, in addressing specific unmet synthetic chemistry challenges faced by the industrial partner (Paraza Pharma Inc., Montreal, QC) with regard to the targeted synthesis and/or modification of heteroatom-dense compounds within proprietary APIs. In particular, the industrial partner requires the development of methodologies that make use of cheap and abundant reaction partners (e.g., heteroaryl chlorides), as well as Earth abundant catalysts (rather than precious metal catalysts that are commonly employed). Once developed, these synthetic protocols can be exploited directly by scientists at Paraza Pharma Inc. in proprietary API synthesis and functionalization. Success in this project will greatly accelerate the industrial partner's drug development program, thereby leading to more rapid identification of novel therapies to the benefit of all Canadians.